WuXi Biologics plans to increase its total manufacturing facility in Massachusetts USA.
The facility is deisgned to increase the total manufacturing capacity 36,000 litres. The construction of the 189,500-square-foot facility is currently in progress.
The new facility will now have the capability to produce 12,000 more litres of commercial drug substance than originally planned, bringing the total planned capacity to 24,000 litres.
This expanded capacity aims to streamline manufacturing processes, making more efficient and cost-effective, ultimately facilitating the production of new biologics for patients.
The facility is expected to commence operations in 2025, and the good manufacturing practise (GMP) release is anticipated in 2026.
When the site reaches full operational capacity, it is anticipated to have a workforce of 250 individuals.
Name WuXi Biologics